3/10 Late treatment study
et al., Press Conference (Preprint)
The Proxa-Rescue AndroCoV Trial
The Proxa-Rescue AndroCoV Trial
RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Cadegiani et al., 3/10/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, baseline oxygen requirements 97.0%, 5 authors.
risk of death, 91.4% lower, RR 0.09, p < 0.001, treatment 12 of 294 (4.1%), control 141 of 296 (47.6%).
risk of mechanical ventilation, 91.6% lower, RR 0.08, p < 0.001, treatment 13 of 294 (4.4%), control 156 of 296 (52.7%).
recovery time, 84.2% lower, relative time 0.16, treatment 294, control 296.
hospitalization time, 64.3% lower, relative time 0.36, treatment 294, control 296.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.